Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

Published:2014-10-06 Issue:12 Volume:16 Page:1257-1264
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Reusch J.¹,Stewart M. W.²,Perkins C. M.³,Cirkel D. T.⁴,Ye J.⁵,Perry C. R.²,Reinhardt R. R.²,Bode B. W.⁶

Affiliation:

1. Department of Endocrinology; Denver Veterans Administration Medical Center; Denver CO USA

2. GlaxoSmithKline; Upper Merion PA USA

3. PPD; Wilmington NC USA

4. GlaxoSmithKline; Stevenage UK

5. GlaxoSmithKline; Research Triangle Park NC USA

6. Atlanta Diabetes Association; Atlanta GA USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12382/fullpdf

Reference21 articles.

1. Report of the committee on the classification and diagnostic criteria of diabetes mellitus;Seino;J Diabetes Investig,2010

2. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary;Garber;Endocr Pract,2013

3. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes;Zinman;Ann Intern Med,2007

4. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD);Zinman;Diabetes Care,2009

5. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus;DeFronzo;Diabetes,2009

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists;Frontiers in Endocrinology;2024-07-24

2. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials;Clinical Cardiology;2024-07

3. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis;Medicine;2024-06-21

4. Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases;Alimentary Pharmacology & Therapeutics;2024-05-30

5. Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies;Cureus;2024-05-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3